Literature DB >> 21750085

Minimal residual disease-directed preemptive treatment with azacitidine in patients with NPM1-mutant acute myeloid leukemia and molecular relapse.

Katja Sockel, Martin Wermke, Jörgen Radke, Alexander Kiani, Markus Schaich, Martin Bornhäuser, Gerhard Ehninger, Christian Thiede, Uwe Platzbecker.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21750085      PMCID： PMC3186324          DOI： 10.3324/haematol.2011.044388

Source DB:  PubMed          Journal:  Haematologica        ISSN： 0390-6078            Impact factor:   9.941


× No keyword cloud information.
  9 in total

1.  Induction of a CD8+ T-cell response to the MAGE cancer testis antigen by combined treatment with azacitidine and sodium valproate in patients with acute myeloid leukemia and myelodysplasia.

Authors:  Oliver Goodyear; Angelo Agathanggelou; Igor Novitzky-Basso; Shamyla Siddique; Tina McSkeane; Gordon Ryan; Paresh Vyas; Jamie Cavenagh; Tanja Stankovic; Paul Moss; Charles Craddock
Journal:  Blood       Date:  2010-06-08       Impact factor: 22.113

Review 2.  Towards individualized follow-up in adult acute myeloid leukemia in remission.

Authors:  Peter Hokland; Hans Beier Ommen
Journal:  Blood       Date:  2010-11-19       Impact factor: 22.113

3.  Successful treatment of molecular relapse in NPM1-positive AML using 5-azacytidine.

Authors:  M Wermke; C Thiede; A Kiani; G Ehninger; M Bornhäuser; U Platzbecker
Journal:  Leukemia       Date:  2009-09-24       Impact factor: 11.528

4.  Maintenance therapy with low-dose azacitidine after allogeneic hematopoietic stem cell transplantation for recurrent acute myelogenous leukemia or myelodysplastic syndrome: a dose and schedule finding study.

Authors:  Marcos de Lima; Sergio Giralt; Peter F Thall; Leandro de Padua Silva; Roy B Jones; Krishna Komanduri; Thomas M Braun; Hoang Q Nguyen; Richard Champlin; Guillermo Garcia-Manero
Journal:  Cancer       Date:  2010-07-29       Impact factor: 6.860

Review 5.  Assessment of minimal residual disease in acute myeloid leukemia.

Authors:  David Grimwade; Paresh Vyas; Sylvie Freeman
Journal:  Curr Opin Oncol       Date:  2010-11       Impact factor: 3.645

6.  Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study.

Authors:  Pierre Fenaux; Ghulam J Mufti; Eva Hellstrom-Lindberg; Valeria Santini; Carlo Finelli; Aristoteles Giagounidis; Robert Schoch; Norbert Gattermann; Guillermo Sanz; Alan List; Steven D Gore; John F Seymour; John M Bennett; John Byrd; Jay Backstrom; Linda Zimmerman; David McKenzie; Cl Beach; Lewis R Silverman
Journal:  Lancet Oncol       Date:  2009-02-21       Impact factor: 41.316

7.  Quantitative assessment of minimal residual disease in acute myeloid leukemia carrying nucleophosmin (NPM1) gene mutations.

Authors:  P Gorello; G Cazzaniga; F Alberti; M G Dell'Oro; E Gottardi; G Specchia; G Roti; R Rosati; M F Martelli; D Diverio; F Lo Coco; A Biondi; G Saglio; C Mecucci; B Falini
Journal:  Leukemia       Date:  2006-06       Impact factor: 11.528

8.  Quantitative monitoring of NPM1 mutations provides a valid minimal residual disease parameter following allogeneic stem cell transplantation.

Authors:  Ulrike Bacher; Anita Badbaran; Boris Fehse; Tatjana Zabelina; Axel Rolf Zander; Nicolaus Kröger
Journal:  Exp Hematol       Date:  2009-01       Impact factor: 3.084

9.  Minimal residual disease levels assessed by NPM1 mutation-specific RQ-PCR provide important prognostic information in AML.

Authors:  Susanne Schnittger; Wolfgang Kern; Claudia Tschulik; Tamara Weiss; Frank Dicker; Brunangelo Falini; Claudia Haferlach; Torsten Haferlach
Journal:  Blood       Date:  2009-07-08       Impact factor: 22.113
  9 in total
  20 in total

Review 1.  Minimal residual disease in acute myeloid leukemia--current status and future perspectives.

Authors:  Sabine Kayser; Roland B Walter; Wendy Stock; Richard F Schlenk
Journal:  Curr Hematol Malig Rep       Date:  2015-06       Impact factor: 3.952

Review 2.  Hypomethylating agents after allogeneic blood stem cell transplantation.

Authors:  Thomas Schroeder; Christina Rautenberg; Rainer Haas; Guido Kobbe
Journal:  Stem Cell Investig       Date:  2016-11-28

3.  Molecular response assessment by quantitative real-time polymerase chain reaction after induction therapy in NPM1-mutated patients identifies those at high risk of relapse.

Authors:  Max Hubmann; Thomas Köhnke; Eva Hoster; Stephanie Schneider; Annika Dufour; Evelyn Zellmeier; Michael Fiegl; Jan Braess; Stefan K Bohlander; Marion Subklewe; Maria-Cristina Sauerland; Wolfgang E Berdel; Thomas Büchner; Bernhard Wörmann; Wolfgang Hiddemann; Karsten Spiekermann
Journal:  Haematologica       Date:  2014-05-09       Impact factor: 9.941

Review 4.  Hypomethylating agents for treatment and prevention of relapse after allogeneic blood stem cell transplantation.

Authors:  Thomas Schroeder; Christina Rautenberg; Rainer Haas; Ulrich Germing; Guido Kobbe
Journal:  Int J Hematol       Date:  2017-11-15       Impact factor: 2.490

Review 5.  Minimal residual disease in acute myeloid leukaemia.

Authors:  Christopher S Hourigan; Judith E Karp
Journal:  Nat Rev Clin Oncol       Date:  2013-06-25       Impact factor: 66.675

Review 6.  Advancing the Minimal Residual Disease Concept in Acute Myeloid Leukemia.

Authors:  Peter Hokland; Hans B Ommen; Matthew P Mulé; Christopher S Hourigan
Journal:  Semin Hematol       Date:  2015-04-07       Impact factor: 3.851

Review 7.  Measurable residual disease testing in acute myeloid leukaemia.

Authors:  C S Hourigan; R P Gale; N J Gormley; G J Ossenkoppele; R B Walter
Journal:  Leukemia       Date:  2017-04-07       Impact factor: 11.528

Review 8.  Minimal Residual Disease in Acute Myeloid Leukemia.

Authors:  Pamela J Sung; Selina M Luger
Journal:  Curr Treat Options Oncol       Date:  2017-01

Review 9.  Incorporating measurable ('minimal') residual disease-directed treatment strategies to optimize outcomes in adults with acute myeloid leukemia.

Authors:  Kristen Pettit; Wendy Stock; Roland B Walter
Journal:  Leuk Lymphoma       Date:  2016-07

Review 10.  Evaluating measurable residual disease in acute myeloid leukemia.

Authors:  Farhad Ravandi; Roland B Walter; Sylvie D Freeman
Journal:  Blood Adv       Date:  2018-06-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.